Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Total Valuation
Fate Therapeutics has a market cap or net worth of $154.63M. The enterprise value is $185.85M.
Market Cap$154.63M
Enterprise Value$185.85M
Share Statistics
Fate Therapeutics has 116,263,460 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding116,263,460
Owned by Insiders13.10%
Owned by Institutions1.72%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -51.39%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.39%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee36.72K
Profits Per Employee-753.12K
Employee Count181
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is ―. Fate Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio17.56
PB Ratio0.56
Price to Fair Value0.56
Price to FCF-1.04
Price to Operating Cash Flow-1.49
PEG Ratio0.03
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 6.65M and earned -136.31M in profits. Earnings per share was -1.15.
Revenue6.65M
Gross Profit-6.25M
Operating Income-147.70M
Pretax Income-136.31M
Net Income-136.31M
EBITDA-127.02M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was -106.08M and capital expenditures -5.95M, giving a free cash flow of -112.04M billion.
Operating Cash Flow-106.08M
Free Cash Flow-112.04M
Free Cash Flow per Share-0.96
Dividends & Yields
Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.86
52-Week Price Change43.63%
50-Day Moving Average1.21
200-Day Moving Average1.18
Relative Strength Index (RSI)49.54
Average Volume (3m)1.61M
Important Dates
Fate Therapeutics upcoming earnings date is May 6, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Fate Therapeutics as a current ratio of 5.79, with Debt / Equity ratio of 37.57%
Current Ratio5.79
Quick Ratio5.79
Debt to Market Cap0.67
Net Debt to EBITDA-0.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fate Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -1.16, with an EV/FCF ratio of -1.32.
EV to Sales22.26
EV to EBITDA-1.16
EV to Free Cash Flow-1.32
EV to Operating Cash Flow-1.39
Balance Sheet
Fate Therapeutics has $203.66M in cash and marketable securities with $77.85M in debt, giving a net cash position of $125.81M billion.
Cash & Marketable Securities$203.66M
Total Debt$77.85M
Net Cash$125.81M
Net Cash Per Share$1.08
Tangible Book Value Per Share$1.74
Margins
Gross margin is -94.12%, with operating margin of -2222.45%, and net profit margin of -2051.08%.
Gross Margin-94.12%
Operating Margin-2222.45%
Pretax Margin-2051.08%
Net Profit Margin-2051.08%
EBITDA Margin-1911.22%
EBIT Margin-2051.08%
Analyst Forecast
The average price target for Fate Therapeutics is $2.25, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$2.25
Price Target Upside69.17% Upside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast-46.92%
EPS Growth Forecast20.26%